|
|
Prevalence, distribution and predictive value of XPO1 mutation in a real‐life chronic lymphocytic leukaemia cohort
Giulia Tueur
,
Gregory Lazarian
,
Virginie Eclache
,
Carole Fleury
,
Rémi Letestu
,
et al.
Journal articles
hal-03942496v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
TP53, XPO1 and ATM Mutations Exclusive Distribution in the Adverse Prognosis Chronic Lymphocytic Leukemia (CLL) Group
Giulia Tueur
,
Virginie Eclache
,
Grégory Lazarian
,
Carole Fleury
,
Rémi Letestu
,
et al.
Conference poster
inserm-03950185v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A primitive plasma cell leukemia with immunoglobulin (Ig) E
Meriem Rachidi
,
Gregory Lazarian
,
Rémi Letestu
,
Daniel Lusina
,
Cedric Desbene
,
et al.
Other publications
hal-03942510v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
Grégory Lazarian
,
Floriane Theves
,
Myriam Hormi
,
Rémi Letestu
,
Virginie Eclache
,
et al.
Journal articles
hal-03557401v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
Anne-Laure Gagez
,
Isabelle Duroux-Richard
,
Stéphane Leprêtre
,
Frédérique Orsini-Piocelle
,
Rémi Letestu
,
et al.
Journal articles
hal-01568353v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial
Anne-Sophie Michallet
,
Rémi Letestu
,
Magali Le Garff-Tavernier
,
Carmen Aanei
,
Michel Ticchioni
,
et al.
Journal articles
hal-03231146v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|